Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Debt (2022 - 2025)

Cue Biopharma (CUE) has disclosed Total Debt for 4 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • Quarterly Total Debt fell 68.85% to $1.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2025, down 68.85% year-over-year, with the annual reading at $4.3 million for FY2024, 46.93% down from the prior year.
  • Total Debt hit $1.6 million in Q3 2025 for Cue Biopharma, down from $2.6 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $10.1 million in Q2 2023 to a low of $1.6 million in Q3 2025.
  • Historically, Total Debt has averaged $7.2 million across 4 years, with a median of $8.2 million in 2023.
  • Biggest five-year swings in Total Debt: increased 1.82% in 2023 and later tumbled 68.85% in 2025.
  • Year by year, Total Debt stood at $10.0 million in 2022, then fell by 18.33% to $8.2 million in 2023, then crashed by 46.93% to $4.3 million in 2024, then crashed by 61.97% to $1.6 million in 2025.
  • Business Quant data shows Total Debt for CUE at $1.6 million in Q3 2025, $2.6 million in Q2 2025, and $3.4 million in Q1 2025.